

## Showing Up

Everyone has their strengths, their specialties, their specific interest. But what are they? What's most popular? Which sessions at ISHLT 2018 garnered the most interest and intrigue, and captivated the largest audience?

### BASIC SCIENCE

#### **Symposium 14 - Old Cells, New Tricks: Updates on Transplant Immunology**

**Chairs:** Stijn Verleden, PhD and Tereza Martinu

**Speakers:** Daniel R Goldstein, MD; Gregor Warnecke, PhD; John R Greenland, MD, PhD; Carla C Baan, PhD; Lori West, MD, DPhil, Andrew Gelman, PhD

**Session Summary:** Graft-specific responses involve a coordinated effort between multiple immune cell types. Exciting advances in transplant immunology are providing insights into these complex interactions that will affect both present and future care for heart and lung allograft recipients. This session will highlight cutting edge transplant immunology research into T, B, and NK lymphocytes and neutrophils, and describe how available therapies affect the cells.

### CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

#### **Symposium 12 - CTEPH: Challenges in Intervention Decision Making**

**Chairs:** Elie Fadel, MD and William Auger, MD

**Speakers:** Mark Toshner, MD; Michael M Madani, MD; Irene Lang, MD; Mithun Chakravarthy, MD; Isabelle Opitz, MD; Joanna Pepke-Zaba, PhD, FRCP; Olaf Mercier, MD; Hiromi Matsubara, MD, PhD

**Session Summary:** This symposium will focus on the key challenges in decision making that physicians face in managing a rising number of patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – especially those with 'early' disease and those with severe, distal disease. Presented in a debate format, this symposium highlights the advantages and disadvantages of each approach in a case based discussion.

### HEART FAILURE & TRANSPLANTATION

#### **Symposium 15 - We Never Stop Learning: 50th Anniversary of Heart Transplantation**

**Chairs:** Maryl R Johnson, MD and Hermann Reichenspurner, MD, PhD

**Speakers:** Brent Evje; Sir Terence English, KBE, FRCS; Marco Masetti, MD; Robert L Page, PharmD, MSPH; Elizabeth H Hammond, MD; Sharon A. Hunt, MD

**Session Summary:** Heart transplantation has evolved from a highly specialized procedure performed at only a handful of centers to a routine treatment option for end-stage heart failure. This session will highlight the historical milestones in surgical techniques, immunosuppression, pathology interpretation, and recipient management that have helped to define the field over the past 50 years.

### INFECTIOUS DISEASES

#### **Symposium 22 - Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape**

**Chairs:** Aric Gregson, MD and Macé M Shuurmans

**Speakers:** Jutta K Preiksaitis, MD; Kovi Levin, MD; Paolo A Grossi, MD, PhD; Lara Danziger-Isakov, MD, MPH; Robin Avery, MD; Kyle Dawson, MBA, BCPS

**Session Summary:** Cytomegalovirus (CMV) continues to present diagnostic and therapeutic challenges for clinicians caring for thoracic organ transplant recipients. Advances in CMV detection, such as quantitative PCR, have introduced uncertainties about when to initiate and cease therapy. Newer CMV immunoassays may

change how we manage CMV. Prolonged prophylactic strategies with valganciclovir have reduced disease incidence, but present new challenges, including resistant and potentially untreatable CMV disease.

## **LUNG FAILURE & TRANSPLANTATION**

### **Symposium 03 - Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now?**

**Chairs:** Cynthia Gries, MD, MSc and Are Martin Holm, MD, PhD

**Speakers:** Robin Vos, MD, PhD; Adrian C Lawrence, MD, MACM; Johanna Kwakkel-van Erp, MD, PhD; Andrew J Fisher, FRCP, PhD; Jamie L Todd, MD; Jens Gottlieb, MD

**Session Summary:** The pathogenesis of CLAD involves both alloimmune and non-alloimmune pathways. This multicouncil forum will present up-to-date knowledge about the pathobiology of CLAD phenotypes including new paradigms of pathophysiology, host-pathogen interactions, the impact of lung microbiome and pulmonary infections upon innate immunity and their impact on CLAD development, diagnosis using more sensitive pulmonary function parameters, radiographic and pathological correlates, and therapeutic strategies.

## **MECHANICAL CIRCULATORY SUPPORT**

### **Symposium 17 - Rapid Update on MCS Complications and Management: The Unpublished**

**Chairs:** Bastian Schmack, MD and Aly El Banayosy, MD

**Speakers:** Andre Vincentelli, MD, PhD; Omar Saeed, MD; Joshua Z Willey, MD, MAS; Jennifer Cowger, MD, MS; Saima Aslam, MD, MS; Susan Joseph, MD; Nir Uriel, MD; Evgenij V Potapov, MD, PhD

**Session Summary:** Mechanical Circulatory Support management is constantly evolving. While serious adverse events such as bleeding, thrombosis, stroke and RV failure are now recognized, comprehensive prevention and treatment strategies have either not been developed or are in constant flux.

## **NURSING, HEALTH SCIENCES & ALLIED HEALTH**

### **Oral Session 12 - The Leading Edge: Novel Practices in Patient Care Pathways**

**Chairs:** Nicola Robinson Smith, RN and Kevin C Carney, MSN, CRNP, CCTC

**Abstract Presenters:** Felix Strangl, MD; Anne Luke, MS; Mohammad Alrawashdeh, PhD, MSN; Felicia Schenkel, NP; Aman Sidhu, MD, MSc; Annette DeVito Dabbs, PhD, RN

## **PATHOLOGY**

### **Oral Session 18 - Mining the Tissue Biopsy: Molecular Signals of Rejection**

**Chairs:** E Rene Rodriguez, MD and Alexandra Rice, FRCPATH

**Abstract Presenters:** Hannah Valentine, MD, MACP; Jean-Paul Duong Van Huyen, MD, PhD; Jeff Reeve, PhD; Fiorella Calabrese, MD; Kieran Halloran, MD

## **PEDATRICS**

### **Symposium 31 - Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction**

**Chairs:** Estela Azeka, MD and Holger W Buchholz, MD

**Speakers:** Katsuhide Maeda, MD; Farhan Zafar, MD; Martin Schweiger, MD, PhD; Kimberly Lin, MD; Steven A Webber, MBChB; Anne Dipchand, MD

**Session Summary:** The goal of this session is to gain a better understanding of the evaluation and treatment of

the failing heart in the intensive care unit setting. This will include discussions on evaluation and treatment of acute heart failure in both cardiomyopathy and congenital heart disease, care of patients on mechanical circulatory support while awaiting heart transplant and care in the ICU after transplantation.

## **PHARMACY & PHARMACOLOGY**

### **Symposium 20 - Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?**

**Chairs:** Haifa Lyster, MSc and Andreas Zuckermann, MD

**Speakers:** Howard Eisen, MD; Erik Verschuuren, MD, PhD; Nicole Kaiser, PharmD, BCOP; Monique Malouf, FRACP; Edward Horn, PharmD

**Session Summary:** The session will cover malignancy after transplantation focusing on causes, epidemiology, effective treatments, and risks associated with immunosuppression minimization.

## **PULMONARY HYPERTENSION**

### **Symposium 29 - Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT**

**Chairs:** Irene Lang, MD and Stephan Rosenkranz, MD

**Speakers:** Jean-Luc Vachiery, MD; Sanjiv J Shah, MD; Stephan Rosenkranz, MD; Susanna Mak, MD, PhD; Nazzareno Galiè, MD, Prof; Mardi Gomberg-Maitland, MD

**Session Summary:** This session, supported by a collaborative effort with the European Society of Cardiology (ESC), will discuss and debate the latest advances in PH due to left heart diseases, the leading cause of PH, after the World Symposium on PH held in Nice (Feb 25th to March 1st 2018). A panel discussion with all speakers will conclude this session.

# ISHLT 2018 Grants & Awards Winners

Please join us in congratulating the following people on being the recipients of the 2018 ISHLT Grants and Awards:

## ISHLT GRANTS & AWARDS

### **Joel D. Cooper Career Development Award**

**Brian Wong, PhD**

Washington University School of Medicine, St. Louis, MO, USA

*The Role of Metabolic Regulation of Lymphangiogenesis and Lymphatic Function in Lung Transplantation*

### **Norman E. Shumway Career Development Award**

**David Schibilsky, MD**

University Medical Center Freiburg, Freiburg, Germany

*Automated Controlled Ex-Vivo Normothermic Perfusion (ac-EVP) of the Heart and Organ Protection by Carbon-Monoxide Application*

### **ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic**

**Kavitha Muthiah, MBChB, PhD, FRACP**

St. Vincent's Hospital, Sydney, NSW, Australia

*Combination of Haemostatic Profile and Vascular Angiogenic Markers as Risk Factors for Gastrointestinal Bleeding - The First Step to Personalization of Antiplatelet Therapy in Continuous Flow Left Ventricular Assist Device Supported Patients*

### **Nursing, Health Sciences & Allied Health Research Grant**

**Martha Abshire, PhD, RN**

Johns Hopkins Hospital, Baltimore, MD, USA

*The Context of VAD Caregiving: A Mixed Methods, Dyadic Study*

**Mary Amanda Dew, PhD**

University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, USA

*Health-Related Quality of Life Outcomes in the Late Years After Cardiothoracic Transplantation*

### **Research Fellowship Award**

**Ei Miyamoto, MD**

Latner Thoracic Surgery Research Laboratories, Toronto, ON, Canada

*Pre-Transplant Lung Allograft Cell Therapy with Expanded Recipient Regulatory T Cells: An Ex-Vivo Lung Perfusion Study*

### **Transplant Registry Early Career Award**

**Hakim Ali, MD**

Duke University Hospital, Durham, NC, USA

*Clinical Features of Lung Transplant Recipients with Prolonged Survival (>15 years) from the ISHLT Registry*

**Daniel Reichart, MD & Liesa Castro, MD**

University Heart Center Hamburg, Hamburg, Germany

*Development and Validation of a Risk Model for Primary Graft Failure After Heart Transplantation and Comparison to the RADIAL Risk Score*

**Laneshia Tague, MD, MSCI**

Washington University, St. Louis, MO, USA

*Association between Allograft Ischemic Time and Adverse Outcomes Following Lung Transplantation*

**Amanda Vest, MBBS, MPH**

Tufts Medical Center, Boston, MA, USA

*The Impact of Pre-Transplant Diabetes of Post-Transplant New Onset Diabetes on Outcomes After Heart Transplantation*

**Michael Yaoyao Yin, MD**

University of Utah School of Medicine, Salt Lake City, UT, USA

*Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices*

## **ISHLT ABSTRACT AWARDS**

### **Early Career Scientist Award in Transplantation**

**Kenneth A Sinclair, BSC (Hons), PhD**

University of Queensland, Brisbane, Australia

*Lysophosphatidic Acid Drives Recirculation and Fibroblastic Differentiation of Mesenchymal Stromal Cells in Chronic Lung Allograft Dysfunction*

### **Philip K. Caves Award**

**Jane O, MD**

Massachusetts General Hospital

*Heart En Bloc Thymus Cotransplantation in NHPs Controls Cellular but not Humoral Activity*

### **JFTC Clinical Case Dilemmas Best Presentation Award**

**Tiffany K. Roberts, PhD**

University of Louisville, Louisville, KY, USA

*Third Party HLA Antibody as a Surrogate Marker for Treatment of Non-HLA AMR*

### **Nursing, Health Sciences & Allied Health Excellence in Research Award**

**Tara E. Miller, FNP**

Duke University Medical Center, Durham, NC, USA

*Breaking the Viral Spiral: Changing How You C Hepatitis*